Publications by authors named "Anna Jakabova"
Article Synopsis
- The study aimed to characterize circulating tumor cells (CTCs) in breast cancer patients undergoing neoadjuvant chemotherapy (NACT) and examine their correlation with tumor volume changes over time.
- Researchers monitored 20 breast cancer patients by analyzing blood samples for CTCs at various chemotherapy stages, utilizing a filtration method to isolate viable cells, and analyzing gene expressions related to cancer and drug resistance.
- Results showed that neoadjuvant chemotherapy effectively reduced tumor volume in some patients, but CTCs persisted in a significant percentage post-treatment, particularly in HER2-positive cases, and their presence correlated with higher relapse rates and shorter progression-free survival.
Introduction: This study analyzes peripheral blood samples from breast cancer (BC) patients. CTCs from peripheral blood were enriched by size-based separation and were then cultivated in vitro. The primary aim of this study was to demonstrate the antigen independent CTC separation method with high CTC recovery.
View Article and Find Full Text PDFArticle Synopsis
- * Testing for CTCs is becoming important for deciding treatment plans and can show how well a treatment is working over time.
- * The study shares experiences with CTC testing in various cancer patients, highlighting its usefulness in treating conditions like breast, colorectal, prostate, and lung cancer.
Article Synopsis
- The study aimed to find cancer cells in the blood of ovarian cancer patients using a new method called MetaCell, which sorts these cells by their size.
- After capturing the cells, they used a special microscope to look at them closely and do more tests on their DNA and RNA.
- The researchers found that certain genes were present in higher amounts in the cancer cells compared to the normal blood, which could help identify ovarian cancer more accurately than using just one gene test.
Delayed diagnosis of ovarian cancer (OC) is usually a cause of its high mortality. OC counts for one of the most aggressive gynecological malignancies. Noninvasive biomarkers may be used to help with diagnostic and treatment decisions in OC management.
View Article and Find Full Text PDF